- Home
- MAXN vs PRLD Comparison
MAXN vs PRLD Comparison
Compare MAXN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAXN
- PRLD
- Stock Information
- Founded
- MAXN 2019
- PRLD 2016
- Country
- MAXN Singapore
- PRLD United States
- Employees
- MAXN N/A
- PRLD N/A
- Industry
- MAXN Semiconductors
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- MAXN Technology
- PRLD Health Care
- Exchange
- MAXN Nasdaq
- PRLD Nasdaq
- Market Cap
- MAXN 61.7M
- PRLD 73.7M
- IPO Year
- MAXN N/A
- PRLD 2020
- Fundamental
- Price
- MAXN $3.02
- PRLD $0.77
- Analyst Decision
- MAXN Sell
- PRLD Strong Buy
- Analyst Count
- MAXN 6
- PRLD 2
- Target Price
- MAXN $195.80
- PRLD $4.50
- AVG Volume (30 Days)
- MAXN 186.0K
- PRLD 254.5K
- Earning Date
- MAXN 05-29-2025
- PRLD 03-10-2025
- Dividend Yield
- MAXN N/A
- PRLD N/A
- EPS Growth
- MAXN N/A
- PRLD N/A
- EPS
- MAXN N/A
- PRLD N/A
- Revenue
- MAXN $689,010,000.00
- PRLD $7,000,000.00
- Revenue This Year
- MAXN N/A
- PRLD N/A
- Revenue Next Year
- MAXN $34.68
- PRLD N/A
- P/E Ratio
- MAXN N/A
- PRLD N/A
- Revenue Growth
- MAXN N/A
- PRLD N/A
- 52 Week Low
- MAXN $2.68
- PRLD $0.63
- 52 Week High
- MAXN $410.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- MAXN 35.05
- PRLD 50.06
- Support Level
- MAXN $2.76
- PRLD $0.71
- Resistance Level
- MAXN $4.26
- PRLD $0.76
- Average True Range (ATR)
- MAXN 0.35
- PRLD 0.07
- MACD
- MAXN 0.02
- PRLD 0.02
- Stochastic Oscillator
- MAXN 17.29
- PRLD 58.46
About MAXN Maxeon Solar Technologies Ltd.
Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.